SP-16 is under clinical development by Serpin Pharma and currently in Phase II for Acute Lung Injury. According to GlobalData, Phase II drugs for Acute Lung Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SP-16 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SP-16 overview

SP-16 is under development for the treatment of type 1 diabetes, chemotherapy-induced peripheral neuropathy (CIPN), type 2 diabetes, myocardial infarction, eosinophilic esophagitis (EoE), chronic inflammatory, demyelinating neuropathy (CIDN), pemphigus vulgaris, acute kidney injury, acute lung injury, atopic dermatitis, alopecia areata and herpes zoster (shingles). The drug candidate is a serpin short peptide, derived from human alpha-1-antitrypsin. The drug candidate is administered through subcutaneous route. It acts by targeting low density lipoprotein receptor related protein 1. 

It was also under development for the treatment of pneumonia due to SARS-CoV-2 infection and its associated ARDS.

Serpin Pharma overview

Serpin Pharma is a biopharmaceutical company that provides the development of targeted therapeutics to enhance the body’s natural immune response. The company’s activities include the isolation of a key portion of a natural SERPIN protein to create a therapeutic SP16, The company’s SP16 is designed to reduce inflammation and restore immune balance, potentially creating a new class of therapeutics for unmet medical needs. Serpin Pharma product indications include patients suffering from inflammatory diseases. Serpin Pharma is headquartered in Manassas, Virginia, the US.

For a complete picture of SP-16’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.